Lexaria Bioscience Corp. (Nasdaq: LEXX) announced on June 25, 2026, that dosing has begun on schedule for Human Pilot Study #7 (GLP-1-H26-7), a five-week trial evaluating two oral DehydraTECH-semaglutide compositions against Novo Nordisk's commercially available Wegovy tablets. The study, which started on June 14th, aims to assess safety, tolerability, and pharmacokinetic performance, potentially positioning Lexaria's DehydraTECH technology for pharmaceutical industry partnerships.
The study investigates three arms comparing SNAC-inclusive DHT-sema formulations in tablet and capsule formats to Wegovy tablets. Conducted under fasted conditions similar to Novo's oral semaglutide products, the five-week duration allows achievement of steady-state concentration levels, where drug input balances with natural elimination. This is a significant advancement from previous single-dose studies, as it provides multi-week data critical for regulatory and commercial evaluation.
Notably, the study incorporates two key enhancements. First, Lexaria is using an oral tablet DHT-sema composition for the first time, designed to mimic the physical properties of Novo's Rybelsus and Wegovy tablets, which temporarily adhere to the stomach lining to optimize absorption. This move aligns with industry standards and aims to increase the likelihood of subsequent commercial relationships. Second, both the DHT-sema tablet and capsule test articles include SNAC, evaluated over a multi-dose, multi-week period for the first time in humans. Previous studies, such as Human Pilot Studies #1 and #2, were single-dose and of shorter duration.
The results of this study are expected to be closely reviewed by the pharmaceutical industry, as they could pave the way for licensing agreements or collaborations centered on Lexaria's DehydraTECH platform. Lexaria's technology has repeatedly demonstrated the ability to improve bio-absorption, reduce side effects, and enhance drug delivery across the blood-brain barrier, as evidenced by its robust intellectual property portfolio with 66 granted patents and additional patents pending worldwide.
The study is fully funded from existing corporate resources, reflecting Lexaria's commitment to advancing oral GLP-1 drug delivery. The company operates a licensed in-house research laboratory and continues to innovate in the drug delivery space, with previous studies showing that DehydraTECH-formulated semaglutide matched or exceeded the performance of Rybelsus while maintaining favorable safety profiles.
For the pharmaceutical industry and patients, the implications are substantial. Oral semaglutide products like Wegovy and Rybelsus have transformed the treatment of type 2 diabetes and obesity, but their bioavailability is limited. Lexaria's technology could enhance oral delivery, potentially improving patient adherence and outcomes. If successful, this study could accelerate the development of more effective oral GLP-1 therapies, benefiting millions of patients worldwide.
Lexaria cautions that forward-looking statements involve risks and uncertainties, including regulatory approvals, scientific discovery, and competitive factors. However, the initiation of this study marks a critical step toward validating DehydraTECH's potential in the rapidly growing GLP-1 market.
